Raymond James Financial Inc. Makes New Investment in Bioventus Inc. (NYSE:BVS)

Raymond James Financial Inc. bought a new stake in shares of Bioventus Inc. (NYSE:BVS) in the 4th quarter, HoldingsChannel.com reports. The firm bought 16,332 shares of the company’s stock, valued at approximately $171,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. HighTower Advisors LLC raised its position in shares of Bioventus by 11.3% during the 4th quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock valued at $143,000 after acquiring an additional 1,380 shares in the last quarter. Principal Financial Group Inc. increased its position in Bioventus by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock worth $202,000 after buying an additional 1,652 shares during the period. Plato Investment Management Ltd acquired a new stake in Bioventus in the fourth quarter worth $38,000. Wells Fargo & Company MN increased its position in Bioventus by 32.0% in the fourth quarter. Wells Fargo & Company MN now owns 22,494 shares of the company’s stock worth $236,000 after buying an additional 5,459 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in Bioventus in the fourth quarter worth $75,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Bioventus

In related news, CFO Mark Leonard Singleton sold 3,875 shares of the firm’s stock in a transaction dated Friday, April 11th. The stock was sold at an average price of $7.57, for a total transaction of $29,333.75. Following the completion of the transaction, the chief financial officer now owns 141,088 shares of the company’s stock, valued at $1,068,036.16. This trade represents a 2.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Anthony D’adamio sold 4,380 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the transaction, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at $1,204,233.82. This represents a 3.57% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 24,208 shares of company stock valued at $226,138. 32.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

BVS has been the subject of several recent analyst reports. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research note on Monday, March 17th. Craig Hallum set a $15.00 price target on Bioventus and gave the stock a “buy” rating in a research note on Wednesday, May 7th.

Bioventus Trading Down 3.0%

NYSE:BVS opened at $6.54 on Wednesday. Bioventus Inc. has a 1 year low of $5.28 and a 1 year high of $14.38. The stock has a market cap of $535.91 million, a price-to-earnings ratio of -10.72 and a beta of 0.95. The business has a fifty day moving average of $8.27 and a 200-day moving average of $9.98. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.